Hamps Bio

Who are the top shareholders of the Hamps Bio?

The top shareholders of Hamps Bio are mainly promoters, with Herrik Mountbaton Shah holding the largest share at 31.12%. Individual investors own 24.66% of the shares, while there are no holdings from mutual funds or foreign institutional investors.

The top shareholders of Hamps Bio are primarily the promoters, with Herrik Mountbaton Shah being the individual with the highest holding at 31.12%. Additionally, individual investors collectively hold 24.66% of the company's shares. There are currently no holdings from mutual funds or foreign institutional investors.

how big is Hamps Bio?

As of Jun 06, Hamps Bio Limited has a market capitalization of 18.00 Cr, classifying it as a Micro Cap company. There is no available financial data for the latest four quarters, with shareholder's funds at 3.37 Cr and total assets of 5.10 Cr as of March 2024.

Market Cap: As of Jun 06, Hamps Bio Limited has a market capitalization of 18.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid Consolidated or Standalone financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of March 2024. Shareholder's Funds are reported at 3.37 Cr, and Total Assets amount to 5.10 Cr.

Has Hamps Bio declared dividend?

No Dividend History Available

What is the technical trend for Hamps Bio?

As of May 29, 2025, Hamps Bio's technical trend is mildly bearish, indicated by the Dow Theory and a lack of bullish signals in the MACD, with the price near its 52-week low and a year-to-date decline of 50.65%.

As of 29 May 2025, the technical trend for Hamps Bio has changed from sideways to mildly bearish. The weekly Dow Theory indicates a mildly bearish stance, and the MACD shows no signal on the weekly and monthly charts. The Bollinger Bands are sideways on the weekly timeframe, suggesting a lack of volatility. The current price is near the lower end of its 52-week range, with a significant decline of 50.65% year-to-date compared to a positive return from the Sensex. Overall, the technical stance is mildly bearish, driven primarily by the Dow Theory and the lack of bullish signals in the MACD.

Who are the peers of the Hamps Bio?

Hamps Bio's peers include IB Infotech, Swasth Foodtech, Vikas Proppant, and others, with varying management risks and growth rates. IB Infotech leads in 1-year returns at 26.92%, while Hamps Bio's return data is unavailable.

Peers: The peers of Hamps Bio are IB Infotech, Swasth Foodtech, Vikas Proppant, Vasudhagama Ent., White Organic, Tarai Foods, Elegant Floricul, Times Green Ener, and Shanti Overseas.<BR><BR>Quality Snapshot: Excellent management risk is observed at IB Infotech, while Good management risk is found at Hamps Bio, and the rest have Below Average management risk. Growth is Excellent at Swasth Foodtech, Good at Vikas Proppant, Average at Vasudhagama Ent., and the rest have Below Average growth. Average capital structure is seen at Hamps Bio, while Excellent capital structure is noted at Vasudhagama Ent., and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is IB Infotech at 26.92%, while the peer with the lowest is Vasudhagama Ent. at -84.88%. Hamps Bio's 1-year return is not available for comparison. Additionally, several peers, including Vasudhagama Ent., Vikas Proppant, White Organic, and Shanti Overseas, have negative six-month returns.

What does Hamps Bio do?

Hamps Bio Limited is a Micro Cap company in the Other Agricultural Products industry, recently renamed from Hamps Bio Private Limited in July 2023. It currently has no reported sales or profit data, with a market cap of INR 16 Cr and a P/E ratio of 16.00.

Overview:<BR>Hamps Bio Limited operates in the Other Agricultural Products industry and is classified as a Micro Cap company.<BR><BR>History:<BR>Hamps Bio Limited was originally incorporated in 2007 as "Hamps Bio Private Limited" and later changed its status to a Public Limited company. The name was officially changed to "Hamps Bio Limited" on July 12, 2023, following the issuance of a fresh Certificate of Incorporation. There is no recent sales or profit data reported.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 16 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 16.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.29<BR>Return on Equity: 8.89%<BR>Price-to-Book: 4.80<BR><BR>Contact Details:<BR>Address: Not available<BR>Phone: Not available<BR>Email: Not available<BR>Website: Not available

What is the bonus history of Hamps Bio?

Hamps Bio recently announced a 1:1 bonus issue, granting shareholders an additional share for each share held, with an ex-date and record date of September 8, 2025.

Hamps Bio has a recent bonus issue where they announced a 1:1 bonus. This means that for every share held, shareholders will receive an additional share. The ex-date for this bonus issue is September 8, 2025, which is also the record date. This is the latest information regarding their bonus history. If you have any more questions about Hamps Bio or need further details, feel free to ask!

Is Hamps Bio overvalued or undervalued?

As of September 9, 2025, Hamps Bio is considered very expensive and overvalued with a PE ratio of 13.07 and an EV to EBITDA of 15.94, significantly lagging behind peers like Sun Pharma and Cipla, while also experiencing a year-to-date return of -27.42% compared to the Sensex's 3.79% gain.

As of 9 September 2025, Hamps Bio's valuation grade has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently considered overvalued based on its financial ratios. The PE ratio stands at 13.07, while the EV to EBITDA ratio is 15.94, and the ROE is a mere 3.41%. <BR><BR>In comparison to its peers, Hamps Bio's valuation metrics are notably less favorable; for instance, Sun Pharma has a PE ratio of 33.36 and an EV to EBITDA of 22.55, while Cipla, rated as attractive, has a PE of 23.28 and an EV to EBITDA of 16.4. This stark contrast highlights Hamps Bio's overvaluation in the current market context. Additionally, the company's recent stock performance has been underwhelming, with a year-to-date return of -27.42%, contrasting sharply with the Sensex's 3.79% gain.

When is the next results date for Hamps Bio?

The next results date for Hamps Bio is 14 November 2025.

The next results date for Hamps Bio is scheduled for 14 November 2025.

How has been the historical performance of Hamps Bio?

Hamps Bio has experienced steady revenue growth, with net sales increasing from 5.58 Cr in Mar'23 to 6.67 Cr in Mar'25, but profitability has declined, with profit after tax dropping from 0.50 Cr in Mar'24 to 0.30 Cr in Mar'25. Despite fluctuations in operating profit and rising costs, the company's equity capital and book value per share have improved, indicating a stronger financial position.

Answer:<BR>The historical performance of Hamps Bio shows a mixed trend in its financial metrics over the past three years.<BR><BR>Breakdown:<BR>Hamps Bio's net sales have increased from 5.58 Cr in Mar'23 to 6.67 Cr in Mar'25, indicating a steady growth in revenue. However, the total operating income has also risen in tandem, reflecting consistent performance. The raw material costs have surged to 0.85 Cr in Mar'25 from 0.21 Cr in Mar'23, while the purchase of finished goods decreased slightly to 2.01 Cr in Mar'25 from 2.17 Cr in Mar'24. Employee costs have risen, contributing to an overall increase in total expenditure, which reached 5.90 Cr in Mar'25 compared to 4.71 Cr in Mar'23. Operating profit (PBDIT) has shown fluctuations, peaking at 1.21 Cr in Mar'24 but dropping to 0.92 Cr in Mar'25. Profit before tax has also decreased from 0.65 Cr in Mar'24 to 0.40 Cr in Mar'25, leading to a profit after tax of 0.30 Cr in Mar'25, down from 0.50 Cr in Mar'24. The company's equity capital has significantly increased to 4.36 Cr in Mar'25 from 1.50 Cr in Mar'23, while total liabilities have risen to 12.67 Cr in Mar'25 from 3.61 Cr in Mar'22. The book value per share has improved to 20.2 in Mar'25 from 4.1875 in Mar'22, indicating a strengthening financial position despite the recent declines in profitability.

Why is Hamps Bio Limited falling/rising?

As of 02-Apr, Hamps Bio Limited's stock price is at 19.79, reflecting a slight decrease of 0.05%. Despite recent strong performance compared to the benchmark, mixed signals arise from today's price decline and reduced investor participation.

As of 02-Apr, Hamps Bio Limited's stock price is currently at 19.79, reflecting a slight decrease of 0.01, or 0.05%. Despite this minor decline, the stock has shown strong performance over the past week, with a notable increase of 9.94%, while the benchmark Sensex has decreased by 2.60% during the same period. Over the past month, the stock has also outperformed the Sensex, gaining 5.21% compared to the benchmark's drop of 8.62%.<BR><BR>However, the stock's year-to-date performance shows a decline of 1.05%, which is better than the Sensex's loss of 13.96%. Over the last year, Hamps Bio Limited has experienced a decrease of 7.95%, while the Sensex has only fallen by 4.30%. This indicates that while the stock has had some recent positive momentum, its longer-term performance has been less favorable compared to the benchmark.<BR><BR>Today's trading activity shows that the stock has outperformed its sector by 0.78%, but there is a concerning trend in investor participation, as the delivery volume has decreased by 28.57% compared to the 5-day average. Additionally, while the stock is trading above its 5-day and 20-day moving averages, it remains below its longer-term moving averages (50-day, 100-day, and 200-day), which could indicate a lack of sustained upward momentum.<BR><BR>In summary, while Hamps Bio Limited has shown recent strength in comparison to the benchmark and sector, the slight decline in price today, coupled with falling investor participation, suggests that there are mixed signals regarding its performance.

Which are the latest news on Hamps Bio?